No Data
Zhongsheng Pharmaceutical Gets Drug Registration for Ulcer Treatment
Guangdong Zhongsheng Pharmaceutical (002317.SZ): obtained the pharmaceutical registration certificate for Brimonidine Tartrate Eye Drops.
On January 14, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that the company has recently received the drug registration certificate for Bromonidine Tartrate Eye Drops approved by the National Medical Products Administration. Bromonidine Tartrate is an alpha-adrenergic agonist that has a dual mechanism of action: it reduces the production of aqueous humor and increases the outflow of aqueous humor through the uveoscleral pathway. Bromonidine Tartrate Eye Drops are clinically used to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. According to the Minai Network database, Bromonidine Tartrate Eye Drops were used in urban public hospitals in China from 2021 to 2023.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Its core products are mainly suitable for the treatment of chronic diseases in the elderly.
On January 9, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform that the company's core products are mostly suitable for the treatment of chronic diseases in the elderly, such as Compound Thrombus Capsule, Cerebral Thrombus Capsule, and Compound Danshen Tablets, among others. The company has partnered with major chain pharmacies to launch the "Caring for the Silver Age•Health for All" project, forming a product package for chronic diseases that combines Compound Thrombus Capsule, Cerebral Thrombus Capsule, and other featured products. The aim is to provide services including testing, patient education, and medication guidance for common diseases in the elderly, empowering county-level chain pharmacies to improve the service system for the elderly with higher quality products and more professional support.
The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.
① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.
Individual Investors Among Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Largest Stockholders and Were Hit After Last Week's 3.6% Price Drop
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The phase II clinical trial of the Innovative Drug RAY1225 injection for lowering blood sugar has obtained top-line analysis data results from the sub-study.
On December 30, Glonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative peptide drug, RAY1225 injection, which is used in the Phase II clinical trial for type 2 diabetes patients, and has recently obtained the top-line analysis data from the sub-study. Preliminary results indicate that RAY1225 injection has shown positive efficacy and good safety in adult participants with type 2 diabetes in China, with the trial results being ideal and achieving the expected objectives.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
